Pharmalicensing is a division of UTEK Corporation; a business development company that has created a progressive open innovation business model to help companies grow rapidly with university, research laboratory and corporate technology.

Pharmalicensing is the leading global marketplace for life sciences business development and licensing and is utilised by over 150, 000 users per month.

Licensing

For licensors - we help innovators market their licensing opportunities to decision makers at licensee organisations worldwide, including bigpharma, biotech companies, spin-offs and academic institutions.

For licensees - we facilitate global pharmaceutical/ biotechnology companies, investors, and research organisations in identifying, tracking and securing of technology opportunities, actively communicating licensing needs, and forming better partnerships.

In addition, we offer a comprehensive partner search, providing clients with a bespoke prospect list of partner search companies entirely based on their partnering criteria. Following client approval this prospect list can then be converted to a ‘hot list' where we will actively introduce our clients, using the Pharmalicensing name, to one another to begin initial discussions.

For outsourced service providers - we market service providers, their skills and expertise to decision makers in pharmaceutical/biotechnology companies worldwide. This industry is becoming increasingly reliant on the expertise of third parties, in order to reduce the time to market and provide access to know-how worldwide.

Pharmalicensing provides a unique approach to business development:

• Access to the largest business development community
• A broadcasting platform used by over 150, 000 users per month
• Direct to potential business partners
• Comprehensive access to business intelligence resources

Listing industry news, timely biopharma reports and details of forthcoming licensing and partnering events, Pharmalicensing provides its users with the relevant mix of intelligence they require in order to strengthen and progress their business development activities further.

More press releases